Login / Signup

Randomized control trial of moderate dose vitamin D alters microbiota stability and metabolite networks in healthy adults.

Madhur WyattAnkan ChoudhuryGabriella Von DohlenJeffery L HeilesonJeffrey S ForsseSumudu RajakarunaManja ZecMalak M TfailyK Leigh Greathouse
Published in: Microbiology spectrum (2024)
Preventative measures to reduce the rise in early-onset colorectal cancer are of critical need. Both vitamin D, dietary and serum levels, and the gut microbiome are implicated in the etiology of colorectal cancer. By understanding the intimate relationship between vitamin D, the gut microbiome, and its metabolites, we may be able to identify key mechanisms that can be targeted for intervention, including inflammation and metabolic dysfunction. Furthermore, the similarity of vitamin D to cholesterol, which is metabolized by the gut microbiome, gives precedence to its ability to produce metabolites that can be further studied and leveraged for controlling colorectal cancer incidence and mortality.
Keyphrases
  • early onset
  • oxidative stress
  • ms ms
  • randomized controlled trial
  • late onset
  • risk factors
  • clinical trial
  • cardiovascular events
  • type diabetes
  • double blind
  • high intensity
  • cancer therapy
  • coronary artery disease